知镜 Cognispect · 医学文献与研究工作台

Mineralocorticoid receptor antagonists for VEGF-pathway inhibitor-associated hypertension and proteinuria: biological rationale, clinical evidence, and a hypothesis-generating framework.

Sagawa T, Umehara K, Izumi M, Kawamura K, Fujikawa K.
Medical oncology (Northwood, London, England) · 2026-11-09 · PMID 43002338

文献摘要

In this narrative review, we integrate mechanistic, clinical, and cardiorenal evidence relevant to mineralocorticoid receptor antagonists (MRAs) in vascular endothelial growth factor (VEGF)-pathway inhibitor-associated hypertension and proteinuria. VEGF-pathway inhibition can cause systemic endothelial dysfunction, altered nitric oxide and endothelin signaling, and heterogeneous glomerular injury, including thrombotic microangiopathy (TMA) with VEGF-ligand blockade and podocytopathy with some VEGFR tyrosine kinase inhibitors. Renin-angiotensin-aldosterone system (RAAS) blockade, dihydropyridine calcium-channel blockers, careful blood pressure control, quantitative proteinuria assessment, and recognition of structural kidney injury remain the established management foundation. MR blockade is biologically attractive because it can lower blood pressure and proteinuria and modulate inflammatory, vascular, and glomerular pathways; however, most supporting evidence is extrapolated from resistant hypertension and chronic kidney disease. Direct oncology evidence is limited to small, nonrandomized datasets and remains hypothesis-generating. Accordingly, MRAs should not be positioned as a preferred third-line antihypertensive class or as established prophylaxis for VEGF-pathway inhibitor-associated renal toxicity. They may be considered as a phenotype-selected option when hypertension and non-nephrotic proteinuria coexist, conventional diuretic escalation is clinically unattractive, product-specific kidney function and potassium criteria are met, and close monitoring is feasible. Prospective oncology studies using kidney-function, structural, and treatment-continuity endpoints are required before routine adoption can be recommended.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。